Scholars Central

Conference abstractPublished 7 Sep 2017

HPMA copolymer-bound doxorubicin as endogenous vaccine substantially increases therapeutic effect of check-point blockade monoclonals: Acute versus chronic model

Authors: Blanka Rihova

Institute of Microbiology AS CR, Czech Republic

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

DOXHYD-HPMA is doxorubicin bound through hydrazone bond to synthetic polymeric carrier based on N-(2- hydroxypropyl)methacrylamide. It is effective anticancer polymeric prodrug with decreased side-toxicity and the ability to induce immunogenic cancer cell death releasing site-specific tumor antigen and thus acting as an endogenous vaccine. We have compared chemo-immunotherapy combination treatment of EL4 T cell lymphoma and 4T1 breast carcinoma with DOXHYD-HPMA and with immune checkpoint blocking anti-CTLA-4 and anti-PD-1 MAbs either alone or in a mixture. To document the role of intestinal microbiota we use germ-free (GF) mice and GF mice monocolonized with Bifidobacterium thetaiotaomicron. Acute model of disease when mice are transplanted once with a lethal dose of tumor cells was compared with chronic model where mice are injected six times every other day with a low number of tumor cells. Healthy mice treated with anti-CTLA-4 and anti-PD-1 mAbs did not show any signs of toxicity while significant co-toxicity was seen in cancer-bearing mice. Treatment with checkpoint inhibitors only exerted a very limited cancer response as no long term survivors (LTS) were recorded. On the other hand more than 60% of mice injected also with therapeutically suboptimal dose of DOXHYD-HPMA survived disease-free for more than 100 days. Those suffering from chronic model of cancer showed considerably higher proportion of PD-1+ cells in tumor microenvironment and reacted substantially better to anti-CTLA-4 or anti-PD-1 treatment than mice with the acute model.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Chemical Engineering & Process Technology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Chemical Engineering & Process Technology
  • SubjectEngineering
  • SubjectChemistry
  • BylineArticles whose byline prints “Blanka Rihova”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels